抄録
Objective: The goal of this study was to determine the effect of etanercept in patients for whom infliximab failed.
Methods: A total of 116 biologically naïve patients with RA (naïve group) and twenty-five patients with RA for whom infliximab failed were treated with etanercept (switching group). Kaplan-Meier survival curves, Disease Activity Score in 28 joints (DAS28), and prednisolone were evaluated at base line, 1, 2, 3, 6 and 9 months after etanercept treatment started.
Results: 58 to 73 percent of patients in the switching group achieved either a moderate or good European League Against Rheumatism (EULAR) score at each point. With regard to continuation rates, there was no difference between the switching group and the naïve group. With regard to moderate or good EULAR scores, there was no difference between switching group and naïve group, except the naïve group was higher than the switching group at 9 months. With regard to decreased rates of prednisolone, the naïve group had a greater decrease than the switching group at 1 month, 2 months and 3 months, respectively. The reasons for stopping etanercept are not related to the reasons for stopping infliximab.
Conclusion: Etanercept is as effective in patients for whom failed infliximab as same as in biologically naïve patients.
